1. Home
  2. Directory
  3. Vermont
  4. Randolph
  5. Physician Assistant
  6. NPI Profile
  7. Prescriptions 1720021918

MS. MARJORIE NIKKI GEWIRZ PA-C
Prescription History 1720021918
Physician Assistant in Randolph, VT

NPI Status: Active since June 14, 2006

Contact Information

44 S MAIN ST
SURGICAL ASSOCIATES
RANDOLPH, VT
ZIP 05060
Phone: (802) 728-2372
Fax: (802) 728-2613

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. MARJORIE NIKKI GEWIRZ PA-C, an active Physician Assistant specialist practicing in Randolph, VT. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 79 documented patient claims. Among these therapy options, the most frequently utilized medication is Buprenorphine-Naloxone, which accounts for 52 claims alone.

Medication Index

B
S
No matching medications currently found on file.

Buprenorphine Hcl

Generic Formulation: Buprenorphine HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 133
VT State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills48.9
Peer Average Days Supply744
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.9% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $371.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$28.60

State Avg Cost Per Claim

$31.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.

Therapeutic Applications

Buprenorphine is used to help relieve severe ongoing pain. Buprenorphine belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain. Do not use this medication to relieve pain that is mild or that will go away in a few days. This medication is not for occasional (as needed) use.

Buprenorphine-Naloxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 52
30-Day Fills 52.0
Days Supply 453
VT State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills73.5
Peer Average Days Supply1,128
Conservative Utilization

This provider writes prescriptions for this formulation 28.8% less frequently than the standard regional baseline metric for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,087.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$78.61

State Avg Cost Per Claim

$108.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Suboxone

Generic Formulation: Buprenorphine Hcl/Naloxone HclSpecialty: Physician Assistant
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 217
VT State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply745
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.9% less volume than the regional standard for practitioners inside VT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,613.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$472.42

State Avg Cost Per Claim

$277.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: buprenorphine and naloxone. It is used to treat opioid dependence/addiction. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. Buprenorphine helps prevent withdrawal symptoms caused by stopping other opioids. Naloxone is an opioid antagonist that blocks the effect of opioids and can cause severe opioid withdrawal when injected. It has little effect when taken by mouth or dissolved under the tongue. It is combined with buprenorphine to prevent abuse and misuse (injection) of this medication. This combination medication is used as part of a complete treatment program for drug abuse (such as compliance monitoring, counseling, behavioral contract, lifestyle changes). Ask your doctor or pharmacist if you should have other forms of naloxone available to treat opioid overdose. Teach your family or household members about the signs of an opioid overdose and how to treat it.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. MARJORIE NIKKI GEWIRZ PA-C provides transparency into local medical care patterns within Randolph, VT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physician Assistant** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.